• Je něco špatně v tomto záznamu ?

Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK+ lung cancer in the kidney transplant recipient

O. Bilek, M. Holanek, J. Jurica, S. Stepankova, J. Vasina, I. Selingerova, A. Poprach, S. Borilova, T. Kazda, I. Kiss, L. Zdrazilova-Dubska

. 2021 ; 99 (-) : 108012. [pub] 20210730

Jazyk angličtina Země Nizozemsko

Typ dokumentu kazuistiky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024916

ALK targeting with tyrosine kinase inhibitors (TKIs) is a highly potent treatment option for the therapy of ALK positive non-small cell lung cancer (NSCLC). However, pharmacokinetics of TKIs leads to clinically significant drug interactions, and the interfering co-medication may hamper the anti-cancer therapeutic management. Here, we present for the first time a drug interaction profile of ALK-TKIs, crizotinib and alectinib, and immunosuppressive agent cyclosporine A in kidney transplant recipients diagnosed with ALK+ lung cancer. Based on therapeutic drug monitoring of cyclosporin A plasma level, the dose of cyclosporine A has been adjusted to achieve a safe and effective therapeutic level in terms of both cancer treatment and kidney transplant condition. Particularly, 15 years upon the kidney transplantation, the stage IV lung cancer patient was treated with the 1st-line chemotherapy, the 2nd-line ALK-TKI crizotinib followed by ALK-TKI alectinib. The successful therapy with ALK-TKIs has been continuing for more than 36 months, including the period when the patient was treated for COVID-19 bilateral pneumonia. Hence, the therapy of ALK+ NSCLC with ALK-TKIs in organ transplant recipients treated with cyclosporine A may be feasible and effective.

000      
00000naa a2200000 a 4500
001      
bmc21024916
003      
CZ-PrNML
005      
20211026134300.0
007      
ta
008      
211013s2021 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.intimp.2021.108012 $2 doi
035    __
$a (PubMed)34339964
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Bilek, Ondrej $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, the Czech Republic; Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 625 00 Brno, the Czech Republic; Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, the Czech Republic
245    10
$a Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK+ lung cancer in the kidney transplant recipient / $c O. Bilek, M. Holanek, J. Jurica, S. Stepankova, J. Vasina, I. Selingerova, A. Poprach, S. Borilova, T. Kazda, I. Kiss, L. Zdrazilova-Dubska
520    9_
$a ALK targeting with tyrosine kinase inhibitors (TKIs) is a highly potent treatment option for the therapy of ALK positive non-small cell lung cancer (NSCLC). However, pharmacokinetics of TKIs leads to clinically significant drug interactions, and the interfering co-medication may hamper the anti-cancer therapeutic management. Here, we present for the first time a drug interaction profile of ALK-TKIs, crizotinib and alectinib, and immunosuppressive agent cyclosporine A in kidney transplant recipients diagnosed with ALK+ lung cancer. Based on therapeutic drug monitoring of cyclosporin A plasma level, the dose of cyclosporine A has been adjusted to achieve a safe and effective therapeutic level in terms of both cancer treatment and kidney transplant condition. Particularly, 15 years upon the kidney transplantation, the stage IV lung cancer patient was treated with the 1st-line chemotherapy, the 2nd-line ALK-TKI crizotinib followed by ALK-TKI alectinib. The successful therapy with ALK-TKIs has been continuing for more than 36 months, including the period when the patient was treated for COVID-19 bilateral pneumonia. Hence, the therapy of ALK+ NSCLC with ALK-TKIs in organ transplant recipients treated with cyclosporine A may be feasible and effective.
650    _2
$a anaplastická lymfomová kináza $x antagonisté a inhibitory $7 D000077548
650    _2
$a karbazoly $x farmakologie $7 D002227
650    _2
$a nemalobuněčný karcinom plic $x farmakoterapie $x patologie $x sekundární $7 D002289
650    _2
$a krizotinib $x farmakologie $7 D000077547
650    _2
$a lékové interakce $7 D004347
650    _2
$a lidé $7 D006801
650    _2
$a transplantace ledvin $7 D016030
650    _2
$a nádory plic $x farmakoterapie $x patologie $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a piperidiny $x farmakologie $7 D010880
650    _2
$a inhibitory proteinkinas $x farmakologie $7 D047428
650    _2
$a tyrosinkinasy $x antagonisté a inhibitory $7 D011505
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
700    1_
$a Holanek, Milos $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, the Czech Republic; Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 625 00 Brno, the Czech Republic
700    1_
$a Jurica, Jan $u Department of Pharmacology, Faculty of Medicine, Masaryk University, 625 00 Brno, the Czech Republic; Hospital Pharmacy, Masaryk Memorial Cancer Institute, 656 53 Brno, the Czech Republic
700    1_
$a Stepankova, Sona $u Center of Cardiovascular and Transplant Surgery, Pekarska 53, 656 91 Brno, the Czech Republic
700    1_
$a Vasina, Jiri $u Department of Nuclear Medicine, Masaryk Memorial Cancer Institute, 656 53 Brno, the Czech Republic
700    1_
$a Selingerova, Iveta $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, the Czech Republic; Department of Pharmacology, Faculty of Medicine, Masaryk University, 625 00 Brno, the Czech Republic
700    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, the Czech Republic; Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 625 00 Brno, the Czech Republic
700    1_
$a Borilova, Simona $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, the Czech Republic; Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 625 00 Brno, the Czech Republic
700    1_
$a Kazda, Tomas $u Department of Radiation oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, the Czech Republic; Department of Radiation oncology, Faculty of Medicine, Faculty of Medicine, Masaryk University, Brno, 625 00 Brno, the Czech Republic
700    1_
$a Kiss, Igor $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, the Czech Republic; Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 625 00 Brno, the Czech Republic
700    1_
$a Zdrazilova-Dubska, Lenka $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, the Czech Republic; Department of Pharmacology, Faculty of Medicine, Masaryk University, 625 00 Brno, the Czech Republic; Department of Clinical Microbiology and Immunology, University Hospital Brno, Jihlavská 25, 625 00 Brno, the Czech Republic. Electronic address: lzd@mail.muni.cz
773    0_
$w MED00006034 $t International immunopharmacology $x 1878-1705 $g Roč. 99, č. - (2021), s. 108012
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34339964 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026134306 $b ABA008
999    __
$a ok $b bmc $g 1714112 $s 1145423
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 99 $c - $d 108012 $e 20210730 $i 1878-1705 $m International immunopharmacology $n Int Immunopharmacol $x MED00006034
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace